Wwox Suppresses Prostate Cancer Cell Growth through Modulation of ErbB2-Mediated Androgen Receptor Signaling
Open Access
- 1 September 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 5 (9) , 957-965
Abstract
The expression of the WWOX tumor suppressor gene is lost or reduced in a large fraction of various cancers, including prostate cancer. We previously reported that Wwox overexpression induced apoptosis and suppressed prostate cancer growth in vitro and in vivo. In this study, pathways through which Wwox contributes to control of prostate cancer cell growth have been investigated. We found that Wwox interacts with Ap2γ and prevents it from entering the nucleus to bind the ERBB2 promoter region to activate transcription of ERBB2, a mediator of androgen receptor activity and prostate cancer cell growth at limiting androgen concentration. Ectopic expression of Wwox reduced ErbB2 protein expression in vitro and expression of Wwox protein inversely correlated with expression of ErbB2 protein in prostate cancer tissues. Furthermore, Wwox suppressed Ap2γ/ErbB2–induced prostate cancer cell growth and suppressed prostate-specific antigen secretion through interaction with Ap2γ and down-modulation of ErbB2, an effect that required functional androgen receptor. (Mol Cancer Res 2007;5(9):957–65)Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- A Role for the WWOX Gene in Prostate CancerCancer Research, 2006
- ErbB Receptor Signaling and Therapeutic Resistance to Aromatase InhibitorsClinical Cancer Research, 2006
- WW Domain–Containing Proteins, WWOX and YAP, Compete for Interaction with ErbB-4 and Modulate Its Transcriptional FunctionCancer Research, 2005
- Concordant loss of fragile gene expression early in breast cancer developmentPathology International, 2005
- Yin Yang 1 Cooperates with Activator Protein 2 to Stimulate ERBB2 Gene Expression in Mammary Cancer CellsJournal of Biological Chemistry, 2005
- KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cellsOncogene, 2004
- Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinomaCancer, 2004
- Activator Protein 2α Inhibits Tumorigenicity and Represses Vascular Endothelial Growth Factor Transcription in Prostate Cancer CellsCancer Research, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpressionBiochemical Journal, 2003